Aimei Health Technology Co., Ltd AFJK FINANCIAL
Company Overview
Aimei Health Technology Co., Ltd does not have significant operations. It intends to effect a merger, share exchange, asset acquisition stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to acquire small cap businesses in the biopharmaceutical, medical technology and device industries, as well as in the diagnostic and other service sectors. Aimei Health Technology Co., Ltd was incorporated in 2023 and is based in New York, New York.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.25.
Recent Developments
- Trailing 12 Months Year-on-year growth — earnings -43.4%.
- 5-Year Trend Long-term compounding — profit CAGR -58.5%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -58.48% |
| 1 Year: | -43.40% |
Stock Price Performance
| 1 Year: | +9.46% |
| 6 Months: | -53.96% |
| 3 Months: | -69.63% |
| 1 Month: | +0.57% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)37.75 · Neutral
P/E of 175.29 is above the sector median of 12.89 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading at a high P/E of 175.3.
- Earnings shrank at -58.5% CAGR over 5 years.
- Trading 86.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Financial Services).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AFJK Aimei Health Technology Co., Ltd FINANCIAL | 12.27 | 175.29 | $38.85M | 0.00% | -9.57% | 13.18% | - | -58.48% |
| 2 | JPM JPMorgan Chase & Co. SPXR3KFINANCIAL | 353.51 | 15.15 | $939.70B | 1.72% | - | 17.79% | 12.50% | 14.83% |
| 3 | BRK-B Berkshire Hathaway Inc. SPXFINANCIAL | 505.83 | 12.72 | $712.23B | 0.00% | - | 12.12% | 4.18% | 9.44% |
| 4 | V Visa Inc. SPXR3KFINANCIAL | 368.64 | 31.35 | $628.20B | 0.72% | 37.15% | 61.19% | 14.33% | 13.04% |
| 5 | MA Mastercard Incorporated SPXR3KFINANCIAL | 570.89 | 31.44 | $496.37B | 0.62% | 60.19% | - | 12.29% | 19.21% |
| 6 | BAC Bank of America Corporation SPXR3KFINANCIAL | 62.39 | 14.41 | $436.28B | 2.04% | - | 11.20% | 3.14% | 4.27% |
| 7 | BRK-A Berkshire Hathaway Inc. FINANCIAL | 757,791.00 | 12.71 | $370.14B | 0.00% | - | 12.12% | 7.60% | 10.02% |
| 8 | HSBC HSBC Holdings plc FINANCIAL | 106.26 | 15.18 | $363.70B | 3.65% | - | 13.10% | 9.75% | 12.72% |
| 9 | MS Morgan Stanley SPXR3KFINANCIAL | 216.24 | 17.48 | $339.62B | 2.26% | - | 17.97% | 3.76% | 9.66% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 413.41K | 41.60K | 130.15K | 250.59K | 61.98K |
| Operating Income | - | -153.63K | -309.11K | -200.02K | - | -413.41K | -41.60K | -130.15K | -250.59K | -61.98K |
| EBITDA | - | - | - | - | - | -413.41K | -41.60K | -130.15K | -250.59K | -61.98K |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | 184.66K | 424.97K | 352.02K | 98.12K | 45.44K |
| Tax Provision | - | - | - | - | - | - | - | - | - | - |
| Net Income | -3.62K | 755.50K | 609.09K | 743.51K | - | 184.66K | 424.97K | 352.02K | 98.12K | 45.44K |
| Diluted EPS | - | - | - | - | - | 0.03 | 0.07 | 0.06 | - | 0.01 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 1.06M | 835.76K |
| Operating Income | -1.06M | -835.76K |
| EBITDA | -1.06M | -835.76K |
| Interest Expense | - | - |
| Pretax Income | 2.55M | 1.06M |
| Tax Provision | - | - |
| Net Income | 2.55M | 1.06M |
| Diluted EPS | 0.28 | 0.17 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 70.47M | 73.81M | 12.10M |
| Current Assets | 580.72K | 30.38K | 2.93K |
| Cash & Equivalents | 580.72K | 28.21K | 2.93K |
| Inventory | - | - | - |
| Receivables | - | - | - |
| Total Liabilities | 714.84K | 1.51M | 4.06M |
| Current Liabilities | 24.84K | 816.99K | 3.37M |
| Long Term Debt | - | - | - |
| Total Debt | - | 227.70K | 2.02M |
| Total Equity | 69.76M | 72.31M | 8.04M |
| Shares Outstanding | 9.03M | 9.03M | 3.17M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -672.29K | -565.10K |
| Investing Cash Flow | -277.70K | 63.58M |
| Financing Cash Flow | 397.48K | -63.04M |
| Capital Expenditure | - | - |
| Free Cash Flow | -672.29K | -565.10K |
| Net Change in Cash | -552.51K | -25.28K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 3.5% | 13.2% |
| ROCE % | -1.5% | -9.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | First Trust Capital Management L.P. | 21.48% | 680.00K | $8.23M |
| 2 | Glazer Capital LLC | 4.22% | 133.74K | $1.62M |
| 3 | Clear Street Group Inc. | 2.63% | 83.34K | $1.01M |
| 4 | Karpus Management, Inc. | 2.44% | 77.12K | $933.21K |
| 5 | SBI Securities Co., Ltd. | - | 112 | $1.35K |
| 6 | UBS Group AG | - | 59 | $713 |
| 7 | Morgan Stanley | - | 43 | $520 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AFJK
AIMEI HEALTH TECHNOLOGY CO., LTD. ANNOUNCES TERMINATION OF BUSINESS COMBINATION AGREEMENT WITH UNITED HYDROGEN GROUP INC.
Aimei Health Technology Co., Ltd. Announces Termination of Business Combination Agreement NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Aimei Health Technology Co., Ltd (NASDAQ: AFJK, AFJKU, AFJKR, the “Company”) announced today that it has t…
AIMEI HEALTH TECHNOLOGY CO., LTD RECEIVES NASDAQ NOTICE REGARDING DELAYED QUARTERLY REPORT
New York, NY, May 20, 2026 (GLOBE NEWSWIRE) -- Aimei Health Technology Co., Ltd (the “Company”) (Nasdaq: AFJK) today announced that on May 19, 2026, it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasda…
AIMEI HEALTH TECHNOLOGY CO., LTD RECEIVES NASDAQ NOTICE REGARDING DELAYED ANNUAL REPORT
New York, NY, April 21, 2026 (GLOBE NEWSWIRE) -- Aimei Health Technology Co., Ltd (the “Company”) (Nasdaq: AFJK) today announced that on April 17, 2026, it received a notice (the “Notice”) from the Listing Qualifications Department of The N…
AFJK — Frequently Asked Questions
What is the current share price of Aimei Health Technology Co., Ltd (AFJK)?
As of 2026-09-19 21:16 PDT, Aimei Health Technology Co., Ltd (AFJK) trades at $12.27 on NasdaqGM. Its 52-week range is $8.00 to $88.50.
What is the market capitalisation of AFJK?
Aimei Health Technology Co., Ltd (AFJK) has a market capitalisation of $38.85M on NasdaqGM.
What is the P/E ratio of AFJK?
AFJK trades at a trailing price-to-earnings (P/E) ratio of 175.29. The industry average P/E is 12.89. Its price-to-book (P/B) ratio is -8.65.
What is the return on equity (ROE) of AFJK?
AFJK has a return on equity (ROE) of 13.18%. Its return on capital employed (ROCE) is -9.57%.
Is AFJK a good stock to buy?
This page provides a data-driven analysis of Aimei Health Technology Co., Ltd (AFJK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.